NCT02143219 2026-04-15
PAMELA70
Institut Cancerologie de l'Ouest
Phase 2 Completed
Clinical Trials
629 trialsNCT00093353 2026-04-14
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00509353 2026-04-14
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00213486 2026-04-06
Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial
University Hospital, Rouen
Phase 2 Completed
NCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
NCT04469556 2026-02-20
PASS-01
University Health Network, Toronto
Phase 2 Completed
NCT04619056 2026-02-19
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
CEBIOTEX
Phase 1 Completed
NCT02021422 2026-02-18
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
Baylor Research Institute
Phase 1 Completed
NCT03365882 2026-02-10
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT04109924 2026-02-10
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Phase 2 Completed
NCT03693807 2026-02-06
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00556413 2026-02-05
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT00989469 2026-02-05
NEXIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT04640480 2026-01-27
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Phase 1 Completed
NCT03366155 2026-01-08
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03290937 2026-01-06
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03443492 2025-12-30
Pancreas
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT02314182 2025-12-19
GRECCAR8
Hospices Civils de Lyon
Phase 3 Completed
NCT04067115 2025-12-17
U01CA236220
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed
NCT05342636 2025-12-17
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03279237 2025-11-25
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Massachusetts General Hospital
Phase 1 Completed
NCT02967289 2025-11-17
IROCAS
UNICANCER
Phase 3 Completed
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02605265 2025-08-28
CinClare
Fudan University
Phase 3 Completed
NCT03797625 2025-07-23
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Phase 2 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT02720068 2025-05-30
MK-4280-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03206151 2025-05-23
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3 Completed
NCT02138617 2025-05-18
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03750669 2025-05-13
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Completed
NCT02896907 2025-04-30
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT03328884 2025-04-23
Phenomenal
MedSIR
Phase 2 Completed
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT00576654 2025-04-15
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT05004350 2025-04-15
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT05379790 2025-04-01
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
Erasmus Medical Center
Phase 1 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT04072198 2025-03-13
NIVACOR
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT04095221 2025-02-20
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT05278728 2025-02-07
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT02162563 2025-02-06
CAIRO5
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT06538207 2025-02-06
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT01814501 2025-02-05
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 2 Completed